M. Meignan et al., Systematic lung scans reveal a high frequency of silent pulmonary embolismin patients with proximal deep venous thrombosis, ARCH IN MED, 160(2), 2000, pp. 159-164
Citations number
35
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Background: A high frequency of asymptomatic pulmonary embolism (PE) has be
en reported in patients with deep venous thrombosis (DVT) in studies of a l
imited number of patients using varying criteria for lung scan assessment.
Objectives: To estimate the frequency of PE using systematic lung scans in
a large group of outpatients with DVT and to compare the results using vary
ing lung scan assessment criteria.
Methods: An international multicenter study comparing 2 different regimens
of low-molecular-weight heparin nadroparin in DVT: perfusion lung scans wer
e performed in 622 outpatients with no clinical indication of PE and with p
roximal DVT confirmed by venography. Three hundred seventy nine of these pa
tients underwent ventilation lung scans. High-probability (HP) scans for PE
were assessed separately using either ventilation scans or chest radiograp
hs to define mismatched perfusion defects.
Results: Perfusion scans showed abnormalities in 82% of the patients; 59% h
ad segmental defects and 30% had normal scans or scans with a very low prob
ability of PE. Depending on the criteria used, 32% to 45% had HP scans for
PE; these percentages were higher in young patients. No relationship was fo
und between extent of thrombosis and HP scans. The estimated frequency of s
ilent PE was 39.5% to 49.5%. During a 3-month follow-up period during which
the patients received therapy, the rate of PE recurrence was low (1.3%) an
d did not differ between patients with baseline HP scans and those with nor
mal scans.
Conclusions: Regardless of what interpretative criteria are used for assess
ing lung scans in PE, the frequency of silent PE is 40% to 50% in patients
with DVT. A baseline lung scan may easily detect PE in these patients but i
s not useful for predicting early thromboembolic recurrences that may occur
during therapy.